What is GMAB's P/E ratio?

GENMAB AS (GMAB) currently trades at a P/E ratio of 21.42.

GENMAB AS reports a Return on Equity (ROE) of 14.45%.

What is GMAB's dividend yield?

GENMAB AS offers a dividend yield of 0.00%.

What is GMAB's Quality Score?

Our AI rates GMAB's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GMAB?

Our AI Timing Score for GMAB is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GMAB belong to?

GENMAB AS is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

GMAB (NASDAQ) Stock Analysis | GENMAB AS

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

GMAB AI Analysis Summary

Our AI summary for GMAB: GENMAB AS (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 21.42, ROE of 14.45%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GMAB

GENMAB AS

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 28.87

0.23 (0.80%) Day Change

Watchlist Portfolio Compare Chart

21.42

P/E

0.92

D/E

14.5%

ROE

6.6%

ROA

0.00%

Div Yield

-2.72

PEG

GENMAB AS
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 28.87 Price 0.23 (0.80%) Day Change	NEWS SCORE: 87

GMAB, the overall quality is not quite good ( Quality = 54) but the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	87
Magic Formula Rank by ROA	1196
Magic Formula Rank by ROE	1196
Magic Formula Rank by ROIC	1558
Price	28.87
PBV / Sector	3.09 / 5.20
Earning Per Share	1.35

PE / Sector	21.42 / 19.97
PEG or PE/Growth / Sector	-2.72 / 1.22
Average 1M Daily Value	59.58 M
Average 1W Daily Value	49.91 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

68%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	21.05 / 98.71 GREAT
NPM Average (%) / Sector	29.48 / -1,721.76 GREAT
NPM Change Average (%) / Sector	-9.86 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	6.63 / 27.02
ROA Average (%) / Sector	12.34 / -368.17
ROA Change Average (%) / Sector	-15.20 / 5,404.12
ROE (%) / Sector	14.45 / 3.47
ROE Average (%) / Sector	17.22 / 6.51
ROE Change Average (%) / Sector	-2.77 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:54
Symbol	GMAB
Name	GENMAB AS
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	613.94 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	17,583.12 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500

Phone: 45 70 20 27 28

Website: https://www.genmab.com

Employees: 3,088

Sector: Healthcare >> Biotechnology

Description: Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.